Loading clinical trials...
Loading clinical trials...
Arnuity Ellipta Drug Use Investigation
The aim of this post-marketing investigation is to collect and assess the information about safety and effectiveness of ARNUITY® ELLIPTA® (hereinafter referred to as "Arnuity") in daily clinical practice. The investigation will include subjects with a diagnosis of asthma bronchial who are naïve to ARNUITY. The investigator will monitor the information about safety and effectiveness of ARNUITY for one year from the start date of ARNUITY administration and Pneumonia will be considered as the priority investigation matter. 300 subjects, from approximately 150 medical institutions, will be included in this analysis. ARNUITY ELLIPTA is the registered trademark of GlaxoSmithKline (GSK) group of companies.
Age
All ages
Sex
ALL
Healthy Volunteers
No
GSK Investigational Site
Hokkaido, Japan
GSK Investigational Site
Nagasaki, Japan
Start Date
August 19, 2017
Primary Completion Date
March 17, 2021
Completion Date
March 17, 2021
Last Updated
April 26, 2021
336
ACTUAL participants
Arnuity Ellipta
DRUG
Lead Sponsor
GlaxoSmithKline
NCT02327897
NCT07219173
NCT07486401
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions